200 related articles for article (PubMed ID: 9703194)
1. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Coyle J; Hobson P; Meara J
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280; author reply 281-2. PubMed ID: 9703194
[No Abstract] [Full Text] [Related]
2. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Heinonen E; Myllylä V
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280-2. PubMed ID: 9703195
[No Abstract] [Full Text] [Related]
3. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Dubois B; Montastruc JL
Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
[No Abstract] [Full Text] [Related]
4. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
5. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
6. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
7. Selegiline and excess mortality.
Oakes D
Clin Neuropharmacol; 1997 Dec; 20(6):542. PubMed ID: 9403228
[No Abstract] [Full Text] [Related]
8. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
9. Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
Bhattacharya KF; Nouri S; Olanow CW; Yahr MD; Kaufmann H
Parkinsonism Relat Disord; 2003 Mar; 9(4):221-4. PubMed ID: 12618057
[TBL] [Abstract][Full Text] [Related]
10. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
[TBL] [Abstract][Full Text] [Related]
11. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Churchyard A; Mathias CJ; Boonkongchuen P; Lees AJ
J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):228-34. PubMed ID: 9285463
[TBL] [Abstract][Full Text] [Related]
12. Controversies in the treatment of Parkinson's disease.
Hely MA; Morris JG
Curr Opin Neurol; 1996 Aug; 9(4):308-13. PubMed ID: 8858190
[TBL] [Abstract][Full Text] [Related]
13. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
Breteler MM
BMJ; 1998 Apr; 316(7139):1182-3. PubMed ID: 9552992
[No Abstract] [Full Text] [Related]
14. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
15. Role of selegiline in combination therapy of Parkinson's disease.
Myllylä VV; Sotaniemi K; Mäki-Ikola O; Rinne UK; Heinonen EH
Neurology; 1996 Dec; 47(6 Suppl 3):S200-9. PubMed ID: 8959989
[No Abstract] [Full Text] [Related]
16. Pallidotomy in Parkinson's disease.
Temlett JA
S Afr Med J; 1996 Oct; 86(10):1248-9. PubMed ID: 8955725
[No Abstract] [Full Text] [Related]
17. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
Jellinger KA
BMJ; 1996 Mar; 312(7032):704-5. PubMed ID: 8597751
[No Abstract] [Full Text] [Related]
18. Moderate Parkinson's disease. Strategies for maximizing treatment.
Silverstein PM
Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
MacMahon DG; Bland R
BMJ; 1996 Mar; 312(7032):703; author reply 704-5. PubMed ID: 8597748
[No Abstract] [Full Text] [Related]
20. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
Gerlach M; Riederer P; Vogt H
BMJ; 1996 Mar; 312(7032):704; author reply 704-5. PubMed ID: 8597750
[No Abstract] [Full Text] [Related]
[Next] [New Search]
